Core Viewpoint - Sanofi Bio's stock decreased by 1.04% to 17.13 CNY per share, with a total market capitalization of 9.597 billion CNY as of the report date [1] Group 1: Company Overview - Sanofi Bio was established on August 7, 2002, and went public on March 19, 2012 [1] - The company specializes in the research, design, production, and sales of point-of-care testing (POCT) products for chronic disease detection [1] - The revenue composition of Sanofi Bio includes: 73.29% from blood glucose monitoring systems, 6.59% from diabetes nutrition and care products, 5.03% from glycated hemoglobin testing systems, 4.14% from blood lipid testing systems, 4.11% from blood pressure monitors, 3.94% from iPOCT monitoring systems, 2.05% from other products, and 0.85% from miscellaneous [1] Group 2: Shareholder Information - Huabao Fund's Huabao CSI Medical ETF (512170) is among the top ten circulating shareholders of Sanofi Bio, having reduced its holdings by 1.5068 million shares in the third quarter, now holding 9.6142 million shares, which is 2.13% of the circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 1.7306 million CNY [2] - The fund was established on May 20, 2019, with a current size of 26.404 billion CNY, yielding 5.42% this year, ranking 3760 out of 4195 in its category [2]

Core Viewpoint - Sanofi Bio's stock experienced a decline of 0.75% on December 29, with a trading volume of 79.52 million yuan, indicating a challenging market environment for the company [1] Financing Summary - On December 29, Sanofi Bio had a financing buy amount of 13.46 million yuan and a financing repayment of 22.77 million yuan, resulting in a net financing buy of -9.31 million yuan [1] - The total financing and securities balance for Sanofi Bio reached 399 million yuan, with the financing balance accounting for 4.10% of the circulating market value, which is above the 70th percentile of the past year [1] - In terms of securities lending, Sanofi Bio repaid 100 shares and sold 6,800 shares, with a selling amount of 117,700 yuan, while the securities lending balance was 1.92 million yuan, exceeding the 90th percentile of the past year [1] Company Overview - Sanofi Bio, established on August 7, 2002, and listed on March 19, 2012, specializes in the research, design, production, and sales of point-of-care testing (POCT) products for chronic disease detection [2] - The company's revenue composition includes: blood glucose monitoring systems (73.29%), diabetes nutrition and care products (6.59%), glycated hemoglobin testing systems (5.03%), blood lipid testing systems (4.14%), blood pressure monitors (4.11%), iPOCT monitoring systems (3.94%), and other products (2.05%) [2] - As of September 30, 2025, Sanofi Bio reported a revenue of 3.45 billion yuan, reflecting a year-on-year growth of 8.52%, while the net profit attributable to shareholders was 211 million yuan, a decrease of 17.36% compared to the previous year [2] Dividend and Shareholder Information - Sanofi Bio has distributed a total of 1.51 billion yuan in dividends since its A-share listing, with 344 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 25.67 million shares, an increase of 3.30 million shares from the previous period [3] - Other notable shareholders include Ruiyuan Growth Value Mixed A and Huabao CSI Medical ETF, with changes in their holdings compared to the previous period [3]

（文章来源：证券日报） 证券日报网讯 12月26日，三诺生物发布公告称，公司将于2025年12月31日召开2025年第一次临时股东 会。 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-098 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于召开2025年第一次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2025 年 12 月 16 日在巨 潮资讯网（www.cninfo.com.cn）上刊登了《关于召开 2025 年第一次临时股东会 的通知》（公告编号：2025-095），公司将于 2025 年 12 月 31 日（星期三）下午 14:30 召开 2025 年第一次临时股东会，本次股东会采用现场投票与网络投票相结 合的方式召开。现将会议有关事项公告提示如下： 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会 2、股东会的召集人：董事会。 3、会议召开的合法、合规性：本次会议的召集、召开符合《中华人民共和 国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引 ...

从资金流向上来看，当日医疗器械板块主力资金净流出6.29亿元，游资资金净流入1.66亿元，散户资金净 流入4.63亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688013 | 天臣医疗 | 54.60 | 3.14% | 4.54万 | | 2.47 Z | | 301122 | 采纳股份 | 27.55 | 2.99% | 2.17万 | | 5943.98万 | | 688108 | 赛诺医疗 | 20.89 | 2.25% | 57.20万 | | 11.64亿 | | 688198 | 佰仁医疗 | 111.02 | 1.67% | 4979.11 | | 5448.99万 | | 300298 | 三诺生物 | 17.44 | 1.34% | 8.40万 | | 1.47亿 | | 688617 | 惠泰医疗 | 250.54 | 1.11% | 7575.15 | | 1.88亿 | | 688755 | 汉邦科技 | 39 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-097 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于选举第六届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）第五届董事会任期即将届 满，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等法律法规、规范性文件及《三诺生物传感股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，公司按照相关法律程序进行董事 会换届选举工作。公司第六届董事会由 7 名董事组成，其中职工代表董事 1 名。 职工代表董事由公司职工通过职工代表大会、职工大会或者其他形式民主选举产 生，无需提交股东会审议。 黄绍波先生，中国国籍，1984 年出生，无境外永久居留权，研究生学历， 毕业于湖南大学工业工程专业，湖南大学工商管理硕士（M ...

Company Overview - Sanor Bio received four medical device registration certificates from the Hunan Provincial Drug Administration, including the "Blood Glucose and Ketone Analyzer" [1] - As of the first half of 2025, Sanor Bio's revenue composition is 99.66% from medical devices and 0.34% from other sources [1] - The current market capitalization of Sanor Bio is 9.5 billion yuan [1]

Core Viewpoint - The company has received four medical device registration certificates from the Hunan Provincial Drug Administration, indicating regulatory approval for new and existing products [1] Group 1: New Product Approval - The new product, a blood glucose, uric acid, and ketone analyzer, has been registered with the certificate number 湘械注准20252220980, valid until December 7, 2030 [1] - This analyzer is designed for quantitative detection of glucose, uric acid, and β-hydroxybutyrate concentrations in various blood samples, including fresh capillary whole blood, venous whole blood, arterial whole blood, and neonatal whole blood [1] Group 2: Continuation of Existing Products - The company has also received continuation registrations for blood glucose test strips and test kits for apolipoprotein A1, apolipoprotein B, creatine kinase, and creatine kinase MB isoenzyme using immunoturbidimetric and rate methods [1]

| 序 | 产品名称 | 注册证编号 | 注册证 | 注册 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 号 | | | 有效期 | 分类 | 产品主要用于体外检测末梢全血中的葡萄糖 | | 3 | 血糖试条 | 湘械注准 20162400157 | 2026.04.15 至 2031.04.14 | II类 | 浓度，可用于医疗机构快速血糖测试，糖尿 病患者或其他人群的血糖监测。本产品只用 于血糖水平的监测，不能用于糖尿病的诊断 和筛查。 | | 载 | 脂 蛋 白 A1/ 载脂蛋白B/肌 酸激酶/肌酸激 | | 2026.04.21 | | 用于体外定量检测人体血清中的载脂蛋白 同 工 | | 酶 4 | 同 工 酶 MB | 湘械注准 | 至 | II类 | A1（ApoA1）与载脂蛋白B（ApoB）的含量， | | | | 20212400522 | | | 肌 酸 激 酶 与 肌 酸 激 酶 酶 (CK) MB | | 检 | 测 试 剂 盒 | | 2031.04.20 | | (CKMB)的活性。 | | | （免疫比浊法/ | | | | | ...

Core Viewpoint - Sanofi Bio's stock has experienced a significant decline of 33.34% this year, with a recent drop of 2.01% on December 23, 2023, reflecting ongoing challenges in the market [1][2]. Group 1: Company Overview - Sanofi Bio, established on August 7, 2002, and listed on March 19, 2012, is located in Changsha, Hunan Province, focusing on the research, design, production, and sales of point-of-care testing (POCT) products for chronic diseases [1]. - The company's main revenue sources include blood glucose monitoring systems (73.29%), diabetes nutrition and care products (6.59%), glycated hemoglobin testing systems (5.03%), blood lipid testing systems (4.14%), blood pressure monitors (4.11%), iPOCT monitoring systems (3.94%), and other products [1]. Group 2: Financial Performance - For the period from January to September 2025, Sanofi Bio reported a revenue of 3.453 billion yuan, representing a year-on-year growth of 8.52%, while the net profit attributable to shareholders decreased by 17.36% to 211 million yuan [2]. - The company has distributed a total of 1.512 billion yuan in dividends since its A-share listing, with 344 million yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Sanofi Bio increased by 58.52% to 24,600, with an average of 18,347 circulating shares per person, a decrease of 37.47% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 25.666 million shares, an increase of 3.297 million shares, while other significant shareholders have seen varying changes in their holdings [3].